| Assessment Status | Rapid Review complete |
| HTA ID | 21067 |
| Drug | Casirivimab/imdevimab |
| Brand | Ronapreve® |
| Indication | For the treatment and prevention of COVID-19. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2021 |
| Rapid review completed | 01/02/2022 |
| Rapid review outcome | On the basis of current evidence, the NCPE recommends that casirivimab/imdevimab not be considered for reimbursement at this time*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.